We are now finishing the work on our next campaign. This is titled "Better use of Menopausal Hormone Therapy (MHT)". We will start offering visits to General Practitioners (GPs) in Norway from september.
The subject of this fifth KUPP-campaign was chosen based on suggestions from GPs, and on dialogue with the Norwegian Association of General Practitioners (NFA).
Medical advisor for KUPP, Specialist in General Medicine and Clinical Pharmacology Ketil Arne Espnes has been leading the group that has developed the materials for the campaign.
– Hormone treatment around menopause is an area where we believe there is a large need for updates for GPs. These hormones were used extensively in the 1990s, but after the publication of the Women’s Health Initiative (WHI) study showed an increased risk with MHT, the use diminished. We now have a much better knowledge base, but in our experience many GPs are uncertain about how to balance the treatment effects with the risk of adverse events. We believe that our campaign can give the GPs better knowledge about how to do these considerations together with their patients.
In addition to Espnes and employees from RELIS and Clinical Pharmacology, the group that has developed the materials for the campaign has consisted of Specialist in Gynecology and Obstetrics Inger Øverlie, and Specialist in General Medicine Hilde Beate Gudim.
– We are very happy that some of the leading experts in Norway has joined us in the development of this campaign Espnes says.
– For KUPP it is very important that our message is credible both with the GPs and with the specialists in gynecology. Inger Øverlie is also leading the revision on the chapter on menopause in the treatment guideline from The Norwegian Society for Gynecology and Obstetrics. This ensures that our information is consistent with the new treatment guideline.
As always, the content of the KUPP campaign is evidence based, and independent from pharmaceutical industry. After having a visit from KUPP, the GP should be updated on the newest and relevant knowledge in this area.
The materials will be finished now during summer. More than 30 employees from RELIS and Clinical Pharmacology will then be trained to deliver visits all over Norway starting in september.